The earnings report itself is overshadowed by the recent dilutive offering. Key near-term catalyst is the EULAR data June 3-6 (complete SLE/SSc data) which could drive a re-rating. Until then, expect pressure from increased share count and cash burn. Monitor for any guidance on pivotal trial timelines.
Price Chart
Executive Summary
Cabaletta Bio reported Q1 2026 net loss of $43.5M (EPS -$0.39, beating consensus of -$0.41 by ~5%) with cash of $116.6M, supplemented by a recent $150M dilutive offering. The earnings were overshadowed by pipeline updates—positive PC-free rese-cel data at ASGCT and progressing registrational myositis trial—but the 51% share dilution from the May 2026 offering and rising operating losses weigh on near-term sentiment.
Key Financial Metrics
Key Facts
- Net loss widened to $43.5M in Q1 2026 from $35.9M in Q1 2025 (21% increase).
- R&D expenses rose 29% to $37.4M, reflecting clinical trial expansion.
- Cash, equivalents, and investments fell to $116.6M from $133.6M at year-end 2025.
- Recent $150M registered direct offering at $2.90/share diluted existing shareholders by ~51%.
- Clinical data: PC-free rese-cel showed drug-free responses in half of PV patients at 6 months; registrational myositis trial advancing.
- Cash runway extended into mid-2027 post offering, but burn rate is accelerating.
Financial Impact
EPS beat consensus by $0.02 (4.9%), but net loss increased $7.6M YoY; 51% dilution from recent offering reduces per-share value.
Risk Factors
- Further dilution if additional capital raises are needed before BLA submission.
- Clinical trial failure or regulatory setbacks for rese-cel.
- Cash burn exceeding projections; need for additional financing.
- Low stock price and reduced liquidity post-offering.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001759138-26-000025 |
| Document: caba-20260514.htm | 0001759138-26-000025 |
| Document: 0001759138-26-000025-index-headers.html | 0001759138-26-000025 |
| Document: 0001759138-26-000025-index.html | 0001759138-26-000025 |
| Document: 0001759138-26-000025.txt | 0001759138-26-000025 |
| 8-K Data (Synthetic) | 0001759138-26-000025 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $2.91 $2.46 | ▼ −15.46% | ▼ −15.57% | $1.91 (−34.36%) |
Aug 15, 2026 6w ago | Institutional Cluster | $2.89 $3.10 | ▲ +7.27% | ▲ +8.46% | $1.91 (−33.91%) |
Aug 13, 2026 7w ago | 8-K | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | $1.91 (−29.52%) |
Aug 13, 2026 7w ago | Press Release | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | $1.91 (−29.52%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.01 $2.84 | ▼ −5.65% | ▼ −6.32% | $1.91 (−36.54%) |
Jun 3, 2026 17w ago | 8-K | $3.58 $3.04 | ▼ −15.08% | ▼ −11.26% | $1.91 (−46.65%) |
Jun 1, 2026 17w ago | DEFA14A | $3.67 $3.25 | ▼ −11.44% | ▼ −8.69% | $1.91 (−47.96%) |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▼ −2.22% | ▼ −2.93% | $1.91 (+47.09%) |
May 14, 2026 20w ago | Press Release | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | $1.91 (−47.09%) |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | $1.91 (−47.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access